Clinical Trial
Eastern Cooperative Oncology Group:
E2A01 Trial for Patients With Amyloidosis
You can learn more about this trial by viewing a short informational video featuring Dr. Morie Gertz, the study chair for this trial:
E2A01 Real Media Video
E2A01 Windows Media Video
Click here for a list of institutions participating in this trial
This trial is looking at whether Amifostine can help make transplants safer for patients with amyloidosis.
If you are placed in the study you will undergo a procedure called stem cell mobilization where cells will be collected from your bloodstream to use in the subsequent transplant. You will then receive amifostine for two days followed by melphalan and one day later your stem cells will be returned.
Patients on this study will be followed for up to ten years to assess the long-term effects of the study treatments.